STAAR Surgical (STAA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of STAAR Surgical (NASDAQ:STAA) have earned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $43.33.

A number of equities research analysts recently commented on STAA shares. BidaskClub upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. Zacks Investment Research lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 2nd. ValuEngine lowered shares of STAAR Surgical from a “strong-buy” rating to a “buy” rating in a report on Friday, December 21st. Finally, TheStreet lowered shares of STAAR Surgical from a “b-” rating to a “c” rating in a report on Friday, December 14th.

Shares of NASDAQ:STAA traded down $1.76 during midday trading on Friday, reaching $34.19. 477,150 shares of the company were exchanged, compared to its average volume of 393,170. STAAR Surgical has a fifty-two week low of $13.60 and a fifty-two week high of $54.00. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of 122.11 and a beta of 2.11.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Thursday, February 21st. The medical instruments supplier reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. STAAR Surgical had a net margin of 4.01% and a return on equity of 13.86%. The business had revenue of $31.19 million for the quarter, compared to analyst estimates of $31.20 million. Equities analysts predict that STAAR Surgical will post 0.3 earnings per share for the current year.

In other STAAR Surgical news, CTO Keith Holliday sold 2,084 shares of STAAR Surgical stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $36.22, for a total value of $75,482.48. Following the sale, the chief technology officer now directly owns 40,239 shares in the company, valued at approximately $1,457,456.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Caren L. Mason sold 7,500 shares of STAAR Surgical stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $36.25, for a total transaction of $271,875.00. Following the completion of the sale, the chief executive officer now owns 44,013 shares in the company, valued at $1,595,471.25. The disclosure for this sale can be found here. Insiders sold a total of 16,730 shares of company stock worth $621,188 over the last quarter. Company insiders own 3.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of STAA. AdvisorNet Financial Inc increased its stake in STAAR Surgical by 600.0% in the 4th quarter. AdvisorNet Financial Inc now owns 875 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 750 shares during the last quarter. First Quadrant L P CA acquired a new position in shares of STAAR Surgical during the 4th quarter worth about $92,000. Bank of Montreal Can increased its stake in shares of STAAR Surgical by 903.3% during the 4th quarter. Bank of Montreal Can now owns 3,050 shares of the medical instruments supplier’s stock worth $97,000 after purchasing an additional 2,746 shares during the last quarter. Amalgamated Bank acquired a new position in shares of STAAR Surgical during the 4th quarter worth about $200,000. Finally, LPL Financial LLC acquired a new position in shares of STAAR Surgical during the 4th quarter worth about $202,000. Hedge funds and other institutional investors own 89.92% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Story: What causes a recession?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.